- Home
- DSY vs XFOR Comparison
DSY vs XFOR Comparison
Compare DSY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- XFOR
- Stock Information
- Founded
- DSY 2020
- XFOR 2014
- Country
- DSY China
- XFOR United States
- Employees
- DSY N/A
- XFOR N/A
- Industry
- DSY
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSY
- XFOR Health Care
- Exchange
- DSY Nasdaq
- XFOR Nasdaq
- Market Cap
- DSY 85.8M
- XFOR 84.3M
- IPO Year
- DSY N/A
- XFOR N/A
- Fundamental
- Price
- DSY $0.61
- XFOR $3.99
- Analyst Decision
- DSY
- XFOR Strong Buy
- Analyst Count
- DSY 0
- XFOR 3
- Target Price
- DSY N/A
- XFOR $34.17
- AVG Volume (30 Days)
- DSY 294.2K
- XFOR 1.6M
- Earning Date
- DSY 01-01-0001
- XFOR 11-07-2025
- Dividend Yield
- DSY N/A
- XFOR N/A
- EPS Growth
- DSY 120.37
- XFOR N/A
- EPS
- DSY 0.01
- XFOR N/A
- Revenue
- DSY $7,323,356.00
- XFOR $32,774,000.00
- Revenue This Year
- DSY N/A
- XFOR $1,307.51
- Revenue Next Year
- DSY N/A
- XFOR N/A
- P/E Ratio
- DSY $49.50
- XFOR N/A
- Revenue Growth
- DSY 16.37
- XFOR 5721.31
- 52 Week Low
- DSY $0.58
- XFOR $1.35
- 52 Week High
- DSY $7.33
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- DSY 28.71
- XFOR 65.29
- Support Level
- DSY $0.60
- XFOR $2.96
- Resistance Level
- DSY $0.79
- XFOR $4.54
- Average True Range (ATR)
- DSY 0.06
- XFOR 0.28
- MACD
- DSY 0.00
- XFOR 0.09
- Stochastic Oscillator
- DSY 11.96
- XFOR 68.39
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.